Effects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patients

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 3, 2014, Pages 277-285

  Derosa, G ^a   Bonaventura, A ^a   Romano, D ^a   Bianchi, L ^a   Fogari, E ^a   D'Angelo, A ^a   Maffioli, P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

enalapril; hypertension; lercanidipine; risk factors

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CD40 LIGAND; ENALAPRIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LERCANIDIPINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; TRIACYLGLYCEROL; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; LIPID; PEROXIDASE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR RISK; CHEMICAL ANALYZER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ESSENTIAL HYPERTENSION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MERCURY SPHYGMOMANOMETER; MONOTHERAPY; MULTICENTER STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; HYPERTENSION; MIDDLE AGED; RISK FACTOR;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR DISEASES; CD40 LIGAND; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; ENALAPRIL; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; PEROXIDASE; RISK FACTORS;

EID: 84899428319     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12139     Document Type: Article

References (43)

1. JNC 7 writing committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003; 289: 2560-2572.
2. Lindqvist M, Kahan T, Melcher A, Hjemdahl P,. Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension, 1994; 24: 287-296.
3. Van der Lee R, Kam KL, Pfaffendorf M, Van Zwieten PA, Differential time course of the vasodilation action of various calcium antagonists. Fundam Clin Pharmacol, 1998; 12: 607-612.
4. Grossman E, Messerli FH,. Effect of calcium antagonists on plasma norepinephrine levels, heart rate and blood pressure. Am J Cardiol, 1997; 80: 1453-1458.
5. Epstein M,. Lercanidipine: a novel dihydropyridine calcium-channel blocker. Heart Dis, 2001; 3: 398-407.
6. Meredith PA,. Lercadinidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity. Expert Opin Investig Drugs, 1999; 8: 1043-1062.
7. Dykewicz MS,. Cough and angioedema from angiotensin converting enzyme inhibitors: new insights into mechanisms and management. Curr Opin Allergy Clin Immunol, 2004; 4: 267-270.
8. Todd PA, Goa KL,. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs, 1992; 43: 346-381.
9. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R,. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med, 1998; 128: 982-988.
10. Hosomi N, Mizushige K, Ohyama H, et al,. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke, 2001; 32: 1539-1545.
11. Rosei EA, Rizzoni D, Muiesan ML, et al,. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens, 2005; 23: 435-444.
12. Motwani JG,. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst, 2002; 3: 72-78.
13. Sica DA,. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs, 2002; 62: 44-62.
14. Barrios V, Escobar C, Calderón A, Echarri R, González-Pedel V, Ruilope LM,; CONTROL RISK Investigators. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROL RISK study. J Hum Hypertens, 2007; 21: 479-485.
15. Rydén L, Standl E, Bartnik M, et al,. Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J, 2007; 28: 88-136.
16. McInnes GT,. Antihypertensive drugs in combination: additive or greater than additive? J Hum Hypertens, 2007; 21: 914-916.
17. Gojanovic B, Feihl F, Liaudet L, Waeber B,. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst, 2008; 9: 1-9.
18. Klose S, Borner K,. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. J Clin Chem Clin Biochem, 1978; 15: 121-130.
19. Wahlefeld AW,. Triglycerides determination after enzymatic hydrolysis. In:, Bergmeyer HU, ed. Methods of Enzymatic Analysis, 2nd English edn. New York: Academic Press, 18-31, 1974.
20. Havel RJ, Eder HA, Bragdon JH,. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest, 1955; 34: 1345-1353.
21. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502.
22. Scanu AM, Scandian L,. Lipoprotein (a): structure, biology and clinical relevance. Adv Intern Med, 1991; 36: 249-270.
23. Uterman G, Weber W,. Protein composition of lipoprotein (a). J Clin Invest, 1987; 80: 458-465.
24. Brett J, Schmidt AM, Yan SD, et al,. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol, 1993; 143: 1699-1712.
25. Graf D, Korthäuer U, Mages HW, Senger G, Kroczek RA,. Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol, 1992; 22: 3191-3194.
26. Morishita K, Kubota N, Asano S, Kaziro Y, Nagata S,. Molecular cloning and characterization of cDNA for human myeloperoxidase. J Biol Chem, 1987; 262: 3844-3851.
27. Winer BJ,. Statistical Principles in Experimental Design, 2nd edn. New York: McGraw-Hill, 1971.
28. Estacio RO, Schrier RW,. Antihypertensive therapy in type 2 diabetes: implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol, 1998; 2: R1-R14.
29. Kasiske BL, Ma JZ, Kalil RSN, Louis TA,. Effects of antihypertensive therapy on serum lipids. Ann Intern Med, 1995; 122: 133-141.
30. Brook RD,. Mechanism of differential effects of antihypertensive agents on serum lipids. Curr Hypertens Rep, 2000; 2: 370-377.
31. Derosa G, D'Angelo A, Mugellini A, Pesce RM, Fogari E, Maffioli P,. Evaluation of emerging biomarkers in cardiovascular risk stratification of hypertensive patients: a 2-year study. Curr Med Res Opin, 2012; 28: 1435-1445.
32. Scanu AM,. Lipoprotein(a). A genetic risk factor for premature coronary heart disease. JAMA, 1992; 267: 3326-3329.
33. Bhavani BA, Padma T, Sastry BKS, Krishna Reddy N,. Plasma Lipoprotein (a) levels in patients with untreated essential hypertension. Indian J Hum Genet, 2003; 9: 65-68.
34. Catalano M, Perilli E, Carzaniga G, Colombo F, Carotta M, Andreoni S,. Lp(a) in hypertensive patients. J Hum Hypertens, 1998; 12: 83-89.
35. Schmidt AM, Vianna M, Gerlach M, et al,. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem, 1992; 267: 14987-14997.
36. Basta G, Schmidt AM, De Caterina R,. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res, 2004; 63: 582-592.
37. Lindsey JB, Cipollone F, Abdullah SM, McGuire DK,. Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res, 2009; 6: 7-14.
38. Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, Huber G,. cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res, 1999; 71: 159-170.
39. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D,. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol, 2005; 25: 1032-1037.
40. Koyama H, Shoji T, Yokoyama H, et al,. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol, 2005; 25: 2587-2593.
41. Ferroni P, Guadagni F,. Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications. Cardiovasc Hematol Disord Drug Targets, 2008; 8: 194-202.
42. Abu-Soud HM, Hazen SL,. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem, 2000; 275: 37524-37532.
43. Eiserich JP, Baldus S, Brennan ML, et al,. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science, 2002; 296: 2391-2394.